An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The study investigations include evaluation of the acute effects of a single dose of
dapagliflozin (10mg), exenatide (5µg), a combination of exenatide and dapagliflozin or
placebo under insulinopenic condition and the long term effect under basal conditions before
and after 12 weeks treatment with dapagliflozin, Exenatide extended release, a combination of
Exenatide extended release and dapagliflozin or placebo on ketogenesis, glucagon and
lipolysis.